Legal turbulence hits the biotech sector as Holzer and Holzer…
Legal turbulence hits the biotech sector as Holzer and Holzer announce an investigation into Capricor Therapeutics. The firm is examining whether the company complied with federal securities laws after the FDA reported that its stem cell treatment for Duchenne muscular dystrophy failed to meet Phase 3 trial objectives, contradicting previous company claims. In the markets, traders are eyeing NASDAQ BEAT for a potential downward move, with technical indicators suggesting a short position as the stock trades below key resistance levels.
- Legal turbulence hits the biotech sector as Holzer and Holzer announce an investigation into Capricor Therapeutics
- The firm is examining whether the company complied with federal securities laws after the FDA reported that its stem cell treatment for…
- In the markets, traders are eyeing NASDAQ BEAT for a potential downward move, with technical indicators suggesting a short position as the…
- Switching to luxury spirits, Colorado residents now have exclusive access to the elusive Weller's bourbon lineup, a move praised by local distillers…